BTG’s (BTG) Neutral Rating Reiterated at JPMorgan Chase & Co.
BTG (LON:BTG)‘s stock had its “neutral” rating reissued by JPMorgan Chase & Co. in a report released on Monday.
A number of other research analysts also recently weighed in on the stock. Numis Securities reaffirmed a “buy” rating and issued a GBX 900 ($12.21) target price on shares of BTG in a research report on Friday, December 8th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 680 ($9.22) target price on shares of BTG in a research report on Tuesday, November 14th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a GBX 775 ($10.51) target price on shares of BTG in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of GBX 771.63 ($10.46).
Shares of BTG (LON BTG) traded down GBX 0.50 ($0.01) during trading hours on Monday, hitting GBX 749.50 ($10.16). 262,253 shares of the company were exchanged, compared to its average volume of 454,235. BTG has a fifty-two week low of GBX 528.36 ($7.17) and a fifty-two week high of GBX 784 ($10.63). The firm has a market capitalization of $2,910.00 and a price-to-earnings ratio of 3,944.74.
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.